Compugen Ltd.

CGEN Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.

2.08 0.08 +4.00%
Market cap
$187.6M
P/E
5.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
7/9
Altman Z
−0.37
Beneish M
−1.59
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— — — 7
ROE
0.00% 42.00% 0.00% 47.85%
ROA
(24.95%) 26.03% 26.68% 23.86%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(39.79%) 28.02% 30.08% 32.75%
Average Days of Receivables
149.74 11.95 11.75 20.27
Free Cash Flow per Share
0.00 1.09 0.00 0.42
Free Cash Flow
— 101.69 — 40.04
Capital Expenditures
— (0.69) — (0.69)
Other line items
Cash ROIC
0.00% 40.94% 0.00% 18.71%
Accounts Receivable Turnover
2.79 28.40 26.49 22.80
Accounts Payable Turnover
0.00 3.16 3.54 4.86
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 92.84 106.28 81.06
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
335.00% 31.28% 32.92% 33.23%
Selling, General and Administrative Expense of Revenue
138.90% 12.96% 12.88% 12.72%
Share Based Compensation of Revenue
0.00% 10.34% 0.00% 8.73%
Operating CF/Net income
0.00 2.90 0.00 1.16
Depreciation/Fixed assets
0.00 (0.92) 0.00 (1.05)
Capex/Depreciation
— 1.10 — 0.95
Revenue per Share
0.07 0.78 0.77 0.78
Operating CF per Share
0.00 1.10 0.00 0.43
Capex per Share
0.00 (0.01) 0.00 (0.01)
Capex to Sales
0.00 0.01 0.00 0.01

Fold the line items

Columns are period end dates